Tion four, Title 45 CFR, Portion 46. Under Monoolein custom synthesis Exemption 4, patient consent

Tion four, Title 45 CFR, Portion 46. Under Monoolein custom synthesis Exemption 4, patient consent just isn’t required and was not obtained for this study, as Title 45 CFR Element 46 does not apply. Specimens had been deidentified plus the clinical information linked with these specimens will not be individually identifiable such that subjects can not be identified either directly or indirectly through identifiers linked towards the subjects. Data Availability Statement: No new data had been developed or analyzed within this study. Information sharing will not be applicable to this article. Acknowledgments: In memory of buddy, husband, and father Kristian Nim, who lost the battle to NSCLC in 2015. Conflicts of Interest: M.D., A.S. and T.M.C. are cofounders of and shareholders in VAR2 Pharmaceuticals (www.var2pharma.com) and VarCT Diagnostics (https://varctdiagnostics.com). N.A.N. can be a consultant for VAR2 Pharmaceuticals. VAR2 Pharmaceuticals and VarCT Diagnostics are biotechnology companies that specialize in therapeutic and diagnostic improvement from the VAR2CSA technologies. G.J.W. is an employee of SOTIO, LCC, outside of this submitted perform, in addition to a former employee of Unum Therapeutics outdoors of this submitted work; reports personal fees from Spring Bank Pharmaceuticals, Imaging Endpoints II, MiRanostics Consulting, Gossamer Bio, Paradigm, International Genomics Consortium, Angiex, IBEX Medical Analytics, GLG Council, Guidepoint Global, Circulogene, and Genomic Overall health, all outdoors this submitted operate; has ownership interest in MiRanostics Consulting, Unum Therapeutics (now Cogent Biosciences), Precise Sciences, Moderna, and Circulogene, outside the submitted operate; and has issued patents PCT/US2008/072787, PCT/US2010/043777, PCT/US2011/020612, and PCT/US20211037616, all outside the submitted work. M.A.T. is an advisor or a consultant for the following institutions: Adaptive, Advisory Board; BMS (Celgene)Connect MDS/AML/MF Registry: Sci Steering Committee; DoximityMedical Advisory Board; Elsevier Clinical Path (prior named: Through Oncology) (1) CoChair Medical Oncology Myeloma Committee, (two) CoChair Healthcare Oncology Lymphoma Committee, and (3) CoChair Medical Hematology ITP Committee; EpizymeAdvisor Board SETD2 inhibitor; JanssenAdvisory BoardDaratumumab; Syapse Precision Medicine Council; TakedaInsightMultiple Myeloma Registry; and UpToDate, Peer Assessment for 4-Epianhydrotetracycline (hydrochloride) Protocol Plasma Cell Dyscrasias. The rest from the authors declare no potential conflicts of interest.
cancersArticleThe Expression Profiles and Deregulation of UDPGlycosyltransferase (UGT) Genes in Human Cancers and Their Association with Clinical OutcomesDong Gui Hu 1, , Shashikanth Marri 2 , Peter I. Mackenzie 1 , JulieAnn Hulin 1 , Ross A. McKinnon 1 and Robyn MeechDicipline of Clinical Pharmacology, College of Medicine and Public Wellness, Flinders University, Bedford Park, SA 5042, Australia; [email protected] (P.I.M.); [email protected] (J.A.H.); [email protected] (R.A.M.); [email protected] (R.M.) Dicipline of Molecular Medicine and Pathology, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia; [email protected] Correspondence: [email protected]; Tel.: 6108Citation: Hu, D.G.; Marri, S.; Mackenzie, P.I.; Hulin, J.A.; McKinnon, R.A.; Meech, R. The Expression Profiles and Deregulation of UDPGlycosyltransferase (UGT) Genes in Human Cancers and Their Association with Clinical Outcomes. Cancers 2021, 13, 4491. https:// doi.org/10.3390/cancers13174491 Academic.